(Q35779267)

10 August 2017

1 reference

title

HIV entry and fusion inhibitors (English)

1 reference

10 August 2017

David Chantry

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

Expert Opinion on Emerging Drugs

10 August 2017

published in

1 reference

10 August 2017

volume

9

1 reference

10 August 2017

issue

1

1 reference

10 August 2017

page(s)

1-7

1 reference

Gulliver's travels in HIVland

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Human immunodeficiency virus type-1 and chemokines: beyond competition for common cellular receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

The global impact of HIV/AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Challenges and opportunities for development of an AIDS vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

The dynamics of CD4+ T-cell depletion in HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Viral dynamics of HIV: implications for drug development and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Strategies in the design of antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Antiretroviral therapy for HIV infection: promises and problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Mechanisms of viral membrane fusion and its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Structure-activity relationship studies: M2 and CCR5 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.1

21 January 2018

Identifiers

DOI

10.1517/14728214.9.1.1

1 reference

10 August 2017

1 reference